Treatment targets relapsed or refractory large B-cell lymphoma
Insurer enlists CVS Health to help in replacing Express Scripts
Announcement follows judge’s ruling to toss patents
Alternative offers better pain relief, could help curb opioid epidemic
Updated data show median overall survival of 30.0 months
Reports indicate he worked to weaken federal efforts to restrict opioids
Figures are even higher for minorities and women
Sophisticated management of life-threatening complications could double cost of care
ALK-positive and ROS1-positive patients benefit


Dr. David B. Nash Talks About Our Health Care Challenges

Dr. David B. Nash, Dean of the Jefferson College of Population Health, talks with P&T Editor Steve McIver about health care reform, value-based treatment, the opioid crisis, telehealth, vaccinations, and our less-than-healthy lifestyles—issues that call for hard work by governments, professions, industry, and every American.

August 2017 interview

P&T October 2017
Table of Contents


Potential Medicare Cut Underlines Need to Rein In Program
In an effort to control costs, the Centers for Medicare and Medicaid Services wants to exact a severe reduction in reimbursement to hospitals that participate in the 340B Drug Pricing Program. The author discusses the program’s shortcomings, the actions taken to address them, and how participating hospitals might be affected by the cut.
Pharmacists are well suited to improve outcomes by delivering medication therapy management (MTM) services. This article presents an MTM pilot program for patients with uncontrolled diabetes that led to significant reductions in hemoglobin A1c.
Vaccine Spotlight
While cholera is not endemic in the U.S., many travelers are at risk for this life-threatening infection. The authors focus on the target population, safety, and efficacy associated with the use of the vaccine for the prophylaxis of cholera.
An electronic P&T committee meeting system that encompasses document sharing, voting, and communication can help multisite institutions unify their formularies across multiple sites. The authors describe one such system designed, developed, and implemented in a large health care system in the Middle East.
Pipeline Plus
Analysts have identified several unmet needs in the HIV therapy marketplace. We present the promising candidates in late-stage clinical development or FDA review.


Prescription: Washington
Off-label drug bills are back on track but could run off the rails
Medication Errors
Misidentification of alphanumeric symbols plays a role in errors
Approvals, new indications, regulatory activities, and more
L-glutamine oral powder (Endari) for reducing the acute complications of sickle cell disease; edaravone (Radicava) for the treatment of amyotrophic lateral sclerosis; and midostaurin (Rydapt) for the treatment of acute myeloid leukemia in combination with chemotherapy
Drug Forecast
Xadago (safinamide), a monoamine oxidase B inhibitor for the adjunct treatment of motor symptoms in Parkinson’s disease